Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
Open Access
- 6 May 2023
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (5) , 655-671
Abstract
The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population–pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population–pharmacokinetics and exposure–response analyses are reviewed.Keywords
Funding Information
- AstraZeneca
This publication has 51 references indexed in Scilit:
- Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus ErythematosusClinical Pharmacokinetics, 2013
- Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alphaClinical Immunology, 2012
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosusArthritis Research & Therapy, 2010
- Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus ErythematosusHuman Genomics and Proteomics, 2009
- A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus ErythematosusImmunity, 2008
- Structural characterization of a human Fc fragment engineered for lack of effector functionsActa Crystallographica Section D Structural Biology, 2008
- Type I interferon correlates with serological and clinical manifestations of SLEAnnals of the Rheumatic Diseases, 2005
- Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active diseaseArthritis & Rheumatism, 2005